vTv Therapeutics Receives FDA's Orphan Drug Designation For HPPD To Treat Sickle Cell Disease

vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to HPPD, the Company’s oral, first-in-class Nrf2/Bach1 modulator. HPPD is being investigated as a treatment for sickle cell disease.